Eisai Overview
- Founded
-
1941
- Status
-
Public
- Employees
-
11,322
- Stock Symbol
-
4523
- Investments
-
16
- Share Price
-
$45.08
- (As of Wednesday Closing)
Eisai General Information
Description
Eisai Co Ltd is a specialty and generic drug manufacturing company. The company's business consists of a pharmaceutical business and other businesses. The pharmaceutical business is categorized by region, including Japan, Americas, China, Asia, and Europe, Middle East, and Africa. Eisai also reports a consumer healthcare business for Japan. The vast majority of the company's revenue is derived by its Japanese pharmaceutical business, followed by its Americas pharmaceuticals segment. The company utilizes licensing strategies in order to expand its research, development, manufacturing, and marketing capabilities.
Contact Information
Primary Industry
Pharmaceuticals
Stock Exchange
TKS
Primary Office
- 4-6-10 Koishikawa
- Bunkyo-ku
- Tokyo, 112-8088
- Japan
+81 00-0000-0000
Eisai Stock Performance
(As of Wednesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $45.08 | $45.23 | $37.52 - $85.58 | $12.9B | 287M | 993K | $1.49 |
Eisai Financials Summary
|
In Thousands, USD |
TTM 31-Mar-2022 | FY 2022 31-Mar-2022 | FY 2021 31-Mar-2021 | FY 2020 31-Mar-2020 |
|---|---|---|---|---|
| EV | 12,052,928 | 12,052,928 | 18,501,938 | 20,319,378 |
| Revenue | 6,731,388 | 6,731,388 | 6,091,522 | 6,397,545 |
| EBITDA | 820,227 | 820,227 | 823,071 | 1,464,162 |
| Net Income | 426,853 | 426,853 | 395,532 | 1,119,877 |
| Total Assets | 10,154,327 | 10,154,327 | 9,866,482 | 9,827,981 |
| Total Debt | 777,506 | 777,506 | 814,871 | 832,206 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Eisai Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Eisai Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Eisai Co Ltd is a specialty and generic drug manufacturing company. The company's business consists of a pharmaceutical
Pharmaceuticals
Tokyo, Japan
11,322
As of 2022
0000
000000
d do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostr
000000000000000
Mumbai, India
00
As of 0000
00.000
00000000000
00.000
000000
lor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint
000000000000000
Lagos, Nigeria
00
As of 0000
Add Comparison
Eisai Competitors (6)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Novartis India | Corporation | Mumbai, India | 00 | 00.000 | 00000000000 | 00.000 |
| 000000000000000 00 | Corporation | Lagos, Nigeria | 00 | |||
| 000000 00000 | Corporation | Mumbai, India | 0000 | |||
| 00000000 | Corporation | Basel, Switzerland | 000000 | 000000000000 | ||
| 000000 00000000000 | Corporation | Tokyo, Japan | 00000 | 00000000 |
Eisai Patents
Eisai Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20220017517-A1 | Substituted piperidine compounds and their use | Pending | 17-Jul-2020 | 0000000000 | |
| US-20220081486-A1 | Anti-bcma antibody-drug conjugates and methods of use | Pending | 05-Jun-2020 | 00000000000 | |
| EP-3868838-A2 | Fluorescent dye and use thereof | Pending | 03-Feb-2020 | 0000000000 | |
| JP-2021123624-A | Fluorescent dye and use thereof | Pending | 03-Feb-2020 | 0000000000 | |
| US-20210255191-A1 | Fluorescent dye and use thereof | Pending | 03-Feb-2020 | C07F7/0816 |
Eisai Executive Team (8)
Eisai Board Members (13)
| Name | Representing | Role | Since |
|---|---|---|---|
| 00000 0000000 | Eisai | Board Member | 000 0000 |
| 00000000 000 | Eisai | Board Member | 000 0000 |
| 00000 00000 | Eisai | Chief Executive Officer & Board Member | 000 0000 |
| 000000 0000000 | Eisai | Board Member | 000 0000 |
| 0000 000000 | Eisai | Chief Executive Officer & Chairman | 000 0000 |
Eisai Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Eisai Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Eisai Investments & Acquisitions (16)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 00000000 | 01-Apr-2022 | 0000000000 | Medical Records Systems | ||
| 00000000 0000 | 27-Jan-2022 | 00000 0000 | 000.00 | Drug Discovery | |
| 000000000 000 | 09-Sep-2021 | 00000 0000 | 0000 | Therapeutic Devices | |
| Ō000 000000 | 01-Jun-2021 | 00000 0000 | 00000 | Monitoring Equipment | |
| Allm (Healthcare Technology Systems) | 05-Apr-2021 | Later Stage VC | 000.00 | Other Healthcare Technology Systems |
Eisai Subsidiaries (2)
| Company Name | Industry | Location | Founded |
|---|---|---|---|
| Eisai Ventures | Corporate Venture Capital | Tokyo, Japan | 2019 |
| 00000000 | Medical Records Systems | Tokyo, Japan | 0000 |
Eisai Exits (4)
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| 0000 (0000000000 0 | 05-Apr-2021 | 00000 00000 00 | 000.00 | Completed |
|
| 00000 | 06-Jan-2010 | 000000000000000000 | 00000 | Completed |
|
| 00000 | 01-Oct-2007 | 0000 | 000.00 | Completed |
|
| EIDIA | 18-Oct-1990 | Merger/Acquisition | 000.00 | Completed |